Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2017 | Key topics on AML at EHA 2017

Oliver Ottmann • 25 Aug 2017
EHA 2017
Acute Myeloid Leukemia

Oliver Ottmann, MD, FRCPath from Cardiff University, Cardiff, UK gives us an overview of four major topics covered at the 2017 European Hematology Association (EHA) annual congress in Madrid, Spain regarding acute myeloid leukemia (AML). Prof. Ottmann talks to us about the impact that these topics, including minimal residual disease analysis, will have in the field of AML research and treatment.

More from Oliver Ottmann

3:38
Impact of increased drug availability on acute leukemia
Oliver Ottmann • 3 Jul 2020
3:24
Molecular profiling to determine treatment for ALL and AML
Oliver Ottmann • 3 Jul 2020
3:07
How age as a prognostic factor affects treatment options for ALL
Oliver Ottmann • 3 Jun 2020
5:23
Treatment options for Ph+ ALL
Oliver Ottmann • 3 Jul 2020

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
3:34
Total marrow and lymphoid irradiation plus cyclophosphamide & etoposide in poor-risk acute leukemias
Anthony Stein • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals